enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. This Beaten-Down Biotech Stock Just Got Some Good News ... - AOL

   www.aol.com/finance/beaten-down-biotech-stock...

   Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This new coverage could also make it easier once CRISPR ...

3. 3 Things You Need to Know if You Buy CRISPR Therapeutics Today

   www.aol.com/3-things-know-buy-crispr-144500442.html

   Image source: CRISPR Therapeutics. 2. Profitability remains elusive. There's some optimism that CRISPR Therapeutics is still in the early stages of a significant long-term opportunity.

4. 1 Biotech Stock Down 62% to Buy and Hold

   www.aol.com/1-biotech-stock-down-62-124500519.html

   CRISPR Therapeutics ended the second quarter with $2 billion in cash, equivalents, and marketable securities, higher than the $1.7 billion it had as of the end of 2023.

5. CRISPR Therapeutics Presents Data at the 2024 American ...

   lite.aol.com/tech/story/0022/20241209/9316263.htm

   ZUG, Switzerland and BOSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented data from the Company’s ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and efficacy of CTX112™, a ...

6. Where Will CRISPR Therapeutics Be in 3 Years? - AOL

   www.aol.com/finance/where-crispr-therapeutics-3...

   CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. But don't expect CRISPR to try to offload ...

7. CRISPR Therapeutics Provides Business Update and Reports ...

   lite.aol.com/tech/story/0022/20241105/9267676.htm

   CRISPR Therapeutics has two next generation approaches with the potential to significantly expand the addressable population with SCD and TDT. The Company continues to advance its internally developed targeted conditioning program, an anti-CD117 (c-Kit) antibody-drug conjugate (ADC), through preclinical studies.

8. 1 big new Green Flag for CRISPR Therapeutics' Stock - AOL

   www.aol.com/finance/1-big-green-flag-crispr...

   CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...

9. FDA Approves First CRISPR Treatment in U.S. - AOL

   www.aol.com/fda-approves-first-crispr-treatment...

   The U.K. had already approved the CRISPR treatment, called exa-cel (brand name: Casgevy), from Vertex Pharmaceuticals and CRISPR Therapeutics (which was co-founded by Charpentier), to treat people ...